相关实验视频

Updated: Jun 27, 2026

Targeted RNA Sequencing Assay to Characterize Gene Expression and Genomic Alterations

Targeted RNA Sequencing Assay to Characterize Gene Expression and Genomic Alterations

Published on: August 4, 2016

在北马其顿肺癌患者中进行基因变异分析

Aleksandar Eftimov¹, Rubens Jovanovic¹, Slavica Kostadinova Kunovska¹

¹Institute of Pathology, Faculty of Medicine, Ss. Cyril and Methodius University, 1000 Skopje, North Macedonia.

|October 29, 2025

概括

这项研究分析了603名肺癌患者的基因变异,发现36.65%患者至少有一种突变. 综合基因测试对于有效的肺癌治疗和患者预后至关重要.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
分子生物学分子生物学

背景情况:

肺癌,包括非小细胞肺癌 (NSCLC) 和小细胞肺癌 (SCLC),由于诊断迟到和治疗效率低下,预后不佳.
开发向疗法需要识别新的癌基因,并彻底调查已知的驱动基因.

研究的目的:

调查八个关键肺癌基因中变化的流行情况:BRAF,EGFR,KRAS,ALK,ROS1,HER2,PD-L1和PIK3CA.

主要方法:

使用实时聚合酶链反应 (RT-PCR) 检测KRAS和EGFR突变.
在KRAS/BRAF/PIK3CA突变中使用多重PCR和微阵列杂交.
进行了针对ALK,HER2/NEU,ROS-1和PD-L1变化的免疫组织化学分析.

主要成果:

603名患者中有36.65% (221) 患有至少一种遗传变异;3.65%患有多种变异.
在KRAS (8.29%),EGFR (7.46%),PIK3CA (1.82%) 和BRAF (0.66%) 中发现了突变.
检测到PD-L1过度表达 (10.45%),ALK重组 (5.31%),HER2/NEU表达 (2.36%),没有ROS-1重组.

结论:

对EGFR,BRAF,KRAS和PIK3CA的体质变异进行全面的测试对于指导肺癌治疗决策至关重要.
建议对肺癌进行常规的基因分析,以实现高效和成本效益的患者管理.
建立完整的遗传资料有助于选择适当的向疗法并改善患者的治疗结果.

关键词:

这就是BRAF.欧洲农业基金会 (EGFR) 是一个.克拉斯 (Kras) 是一个国家.基因的改变基因的改变肺癌是一种肺癌.

更多相关视频

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...